Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mellor, G. W.
Right arrow Articles by Banks, M. N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mellor, G. W.
Right arrow Articles by Banks, M. N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Development of a CD28/CD86 (B7-2) Binding Assay for High Throughput Screening by Homogeneous Time-Resolved Fluorescence

Geoffrey W. Mellor

Lead Discovery Unit, Glaxo Wellcome Research and Development, Stevenage, England

M. Neil Burden

Immunopathology Unit, Glaxo Wellcome Research and Development, Stevenage, England

Marc Preaudat

CIS biointernational, Marcoule, France

Yvonne Joseph

Lead Discovery Unit, Glaxo Wellcome Research and Development, Stevenage, England

Susan B. Cooksley

Immunopathology Unit, Glaxo Wellcome Research and Development, Stevenage, England

Jonathan H. Ellis

Immunopathology Unit, Glaxo Wellcome Research and Development, Stevenage, England

Martyn N. Banks

Lead Discovery Unit, Glaxo Wellcome Research and Development, Stevenage, England

CD28 has been demonstrated to provide the major costimulatory signal for CD4-positive T cells. Ligation with its natural ligands CD80 (B7-1) and CD86 (B7-2) leads to signals during activation that are required for the production of interleukin-2, and this process has been implicated in the regulation of T-cell anergy and programmed cell death. This article describes the assay development, assay validation, and primary screening for small molecule antagonists of this interaction, which could be potential drug candidates. The assay uses homogeneous time-resolved fluorescence based on energy transfer from excited europium ions to cross-linked allophycocyanin, which then subsequently emits a fluorescent signal. An "indirect" approach was taken, whereby the cross-linked allophycocyanin (XL665) is covalently linked to an antihuman antibody that binds to a human immunoglobulin (Ig) domain fused to CD28. The CD86 that is expressed as a fusion protein with a rat Ig domain is bound to biotinylated sheep antirat antibody, which is complexed with streptavidin-europium cryptate. This "cassette" format facilitates the development of related assays using CTLA-4 in place of CD28 and/or CD80 in place of CD86, allowing easy determination of the selectivity of active compounds. When the CD28 and CD86 are in close proximity (i.e., bound), there is a specific time-resolved emission at 665 nm that is largely absent in either unbound partner. Experiments to optimize the reagent concentrations, incubation time, solvent effects and quench effects by colored compounds are discussed, as are the results from robustness testing and data from primary screening.

Journal of Biomolecular Screening, Vol. 3, No. 2, 91-99 (1998)
DOI: 10.1177/108705719800300205
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
K. Uvebrant, D. Da Graca Thrige, A. Rosen, M. Akesson, H. Berg, B. Walse, and P. Bjork
Discovery of Selective Small-Molecule CD80 Inhibitors
J Biomol Screen, June 1, 2007; 12(4): 464 - 472.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
M. Preaudat, J. Ouled-Diaf, B. Alpha-Bazin, G. Mathis, T. Mitsugi, Y. Aono, K. Takahashi, and H. Takemoto
A Homogeneous Caspase-3 Activity Assay Using HTRF(R) Technology
J Biomol Screen, June 1, 2002; 7(3): 267 - 274.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
M. D. Boisclair, C. McClure, S. Josiah, S. Glass, S. Bottomley, S. Kamerkar, and I. Hemmila
Development of a Ubiquitin Transfer Assay for High Throughput Screening by Fluorescence Resonance Energy Transfer
J Biomol Screen, October 1, 2000; 5(5): 319 - 328.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
K. Enomoto, Y. Aono, T. Mitsugi, K. Takahashi, R. Suzuki, M. Preaudat, G. Mathis, G. Kominami, and H. Takemoto
High Throughput Screening for Human Interferon-y Production Inhibitor Using Homogenous Time-Resolved Fluorescence
J Biomol Screen, August 1, 2000; 5(4): 263 - 268.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
J. B. McMahon, J. A. Beutler, B. R. O'Keefe, C. B.B. Goodrum, M. A. Myers, and M. R. Boyd
Development of a Cyanovirin-N-HIV-1 gpl20 Binding Assay for High Throughput Screening of Natural Product Extracts by Time-Resolved Fluorescence
J Biomol Screen, June 1, 2000; 5(3): 169 - 176.
[Abstract] [PDF]

Home page
 J Biomol ScreenHome page
A. J. Pope
Introduction LANCETM vs. HTRF(R) Technologies (or Vice Versa)
J Biomol Screen, December 1, 1999; 4(6): 301 - 302.
[PDF]

Home page
 J Biomol ScreenHome page
G. Mathis
HTRF(R) Technology
J Biomol Screen, December 1, 1999; 4(6): 309 - 313.
[PDF]